
|Videos|December 23, 2020
ASH 2020 Updates: Improving Outcomes in TIE-NDMM
Author(s)Targeted Oncology
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GI Cancer Highlights: Beyond the LBAs
2
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
5


































